SCM
BCRX icon

Silverarc Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Silverarc Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-248,728
Closed -$1.49M – 82
2023
Q4 		$1.49M Sell
248,728
-542,943
-69% -$3.15M 0.46% 54
2023
Q3 		$5.61M Buy
791,671
+30,767
+4% +$221K 2.09% 23
2023
Q2 		$5.36M Buy
760,904
+183,147
+32% +$1.47M 1.81% 20
2023
Q1 		$4.82M Buy
577,757
+305,584
+112% +$2.94M 2.17% 20
2022
Q4 		$3.12M Buy
272,173
+85,570
+46% +$1.07M 1.08% 40
2022
Q3 		$2.35M Buy
186,603
+133,082
+249% +$1.71M 1% 40
2022
Q2 		$566K Sell
53,521
-48,904
-48% -$504K 0.27% 62
2022
Q1 		$197 Buy
+102,425
New +$1.64M 0.09% 63
2021
Q1 		– Sell
-110,000
Closed -$820K – 93
2020
Q4 		$820K Buy
+110,000
New +$567K 0.5% 54

Other funds holding BCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $22.1B AUM 51.63% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return